Abstract submission is now closed
View the abstracts in the online programme
Abstract submission deadlines
Abstracts |
Deadline |
|---|---|
|
Abstracts Trial in Progress Intent to submit LBA |
Tuesday, 21 February 2023, 21:00 CET |
Late-breaking abstracts |
Final submission deadline Wednesday, 12 April 2023*, 21:00 CEST |
Outcome notifications
Outcome notifications are expected to be made available to first authors and submitters by mid-/end-March 2023.
Outcome notifications of accepted full LBAs are expected to be made available to first authors and submitters by 20 April 2023.
Information for presenters
Detailed instructions for the preparation of slides presentations and posters will be made available by mid-/end-March in the section "Information for Presenters".
Abstract submission categories
- Biomarkers and translational research and precision medicine
- Early breast cancer: Adjuvant therapy
- Early breast cancer: Neoadjuvant therapy
- Early breast cancer: Surgery and radiotherapy
- Early detection, hereditary breast cancer and prevention
- Metastatic breast cancer
- Supportive care and survivorship
- Miscellaneous
Late-breaking abstracts
Late-breaking abstracts may be submitted for high quality, new research findings with implications for clinical practice or understanding of disease processes. The work must not have been previously published in any publication in a peer review setting or presented at a meeting of any other scientific organisation prior to ESMO Breast Cancer 2023.
Only abstracts for which no conclusive data are available at the time of the abstract submission deadline of 21 February 2023 will be considered for late-breaking status.
The final late-breaking abstract deadline of 12 April 2023 is under no circumstances to be considered as an extension of the general submission deadline.
Trial in Progress abstracts
Trial in Progress (TiP) abstracts in all phases of clinical research (phases I to III) may be submitted to ESMO Breast Cancer 2023.
It is expected that abstracts submitted as Trial in Progress are ongoing trials that have not reached any protocol-specified endpoints for analysis.
Presentation of accepted abstracts
The Breast Cancer 2023 Scientific Committee will select abstracts for presentation during the Congress and determine the format of the presentations from the following possibilities:
- Proffered Paper – Oral presentations by authors presenting original data of superior quality, followed by expert discussion and perspectives.
- Mini Oral – Short oral presentations by authors presenting data of good quality, followed by expert discussion and perspectives.
- Poster – Display session for review, discussion and questions. The presenting authors must be available for Q&A to represent their work.
All accepted abstracts, including Late-breaking, will be published online in the ESMO Breast Cancer 2023 Abstract Book, a supplement to the official ESMO journal, ESMO Open.
Publication schedule of accepted abstracts
Please refer to the schedule here
ESMO Merit Travel Grant
A restricted number of ESMO Merit Travel Grants to the ESMO Breast Cancer 2023 are available, upon application, to first author (= presenter) who submit abstracts considered to be deserving of recognition. Candidates must be ESMO Members under the age of 40. Selection will be made by the ESMO Breast Cancer 2023 Scientific Committee on a competitive basis from among the accepted abstracts.